Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CPIX | 8-K | neutral | 4/10 | Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for s | Oct 23, 2026 |
| APVO | 8-K | neutral | 2/10 | Aptevo Therapeutics filed an 8-K to amend its shareholder rights plan (poison pill), extending the expiration date by on | Oct 23, 2026 |
| PHAT | 8-K | bearish | 6/10 | Phathom disclosed that BDR Pharmaceuticals has sued the FDA challenging the agency's refusal to accept an ANDA referenci | Oct 23, 2026 |
| MTEX | 8-K/A | bearish | 5/10 | Mannatech filed this 8-K/A to add the required auditor letter (Exhibit 16.1) from former auditor BDO USA, P.C., confirmi | Oct 23, 2026 |
| ACAD | 8-K | neutral | 3/10 | Acadia Pharmaceuticals filed an 8-K confirming the departure of Elizabeth H.Z. Thompson, Ph.D., Executive Vice President | Oct 23, 2026 |
| SAFX | 8-K | bullish | 6/10 | XCF Global (SAFX) entered into a definitive agreement to acquire a sustainable aviation fuel (SAF) production facility i | Oct 23, 2026 |
| AEON | 8-K | neutral | 4/10 | AEON Biopharma filed an 8-K furnishing an October 2026 corporate presentation that outlines its strategy to develop ABP- | Oct 23, 2026 |
| RCUS | 8-K | bearish | 5/10 | Arcus Biosciences closed a public offering of 16,428,572 shares of common stock at $17.50 per share, including full exer | Oct 23, 2026 |
| CTOR | 8-K | bearish | 5/10 | Citius Oncology received a Nasdaq extension through April 19, 2027, to regain compliance with the $1.00 minimum bid pric | Oct 23, 2026 |
| AKBA | 8-K | bearish | 7/10 | Akebia Therapeutics received a Nasdaq deficiency notice on October 21, 2026, because its common stock bid price closed b | Oct 23, 2026 |
| AMRX | 8-K/A | neutral | 5/10 | Amneal Pharmaceuticals filed an 8-K/A providing unaudited pro forma financial statements for its acquisition of Kashiv B | Oct 23, 2026 |
| AARD | 8-K | mixed | 6/10 | Aardvark Therapeutics reported exploratory efficacy data from its terminated Phase 3 HERO trial and open-label extension | Oct 23, 2026 |
| ONCO | 8-K | neutral | 3/10 | Onconetix made an additional $500,000 advance to Realbotix under an existing Grid Promissory Note, bringing total outsta | Oct 23, 2026 |
| CATX | 8-K | bullish | 6/10 | Perspective Therapeutics reported updated interim Phase 1/2a data for [212Pb]VMT-α-NET (bamzireotide navoxetan) in SSTR2 | Oct 23, 2026 |
| BOLT | 8-K | mixed | 7/10 | Bolt Biotherapeutics (BOLT) has entered into a definitive merger agreement to acquire Prana Therapies in a reverse-merge | Oct 23, 2026 |
| EIKN | 8-K | neutral | 4/10 | Eikon Therapeutics presented initial and updated clinical data from its PARP1-selective (EIK1003, EIK1004) and WRN helic | Oct 23, 2026 |
| ORIC | 8-K | bullish | 7/10 | ORIC Pharmaceuticals presented updated Phase 1b data for enozertinib in 1L EGFR atypical NSCLC at ESMO 2026, showing an | Oct 23, 2026 |
| SXTP | 8-K | neutral | 4/10 | 60 Degrees Pharmaceuticals filed an 8-K furnishing an updated investor presentation (October 23, 2026) detailing progres | Oct 23, 2026 |
| NEUP | 8-K | neutral | 2/10 | Neuphoria Therapeutics extended the expiration date of its shareholder rights plan (poison pill) by one year, from Octob | Oct 23, 2026 |
| TNGX | 8-K | bullish | 7/10 | Tango Therapeutics reported highly promising Phase 1/2 data for vopimetostat + daraxonrasib in MTAP-deleted PDAC, showin | Oct 23, 2026 |
| ZYME | 8-K | bullish | 7/10 | Zymeworks entered into an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T-cel | Oct 23, 2026 |
| ZLAB | 8-K | bullish | 6/10 | Zai Lab announced a $250M PIPE financing, selling 11.34M ADSs at $22.04/ADS to a syndicate of healthcare-focused investo | Oct 23, 2026 |
| LNAI | 8-K | bearish | 9/10 | Lunai Bioworks received a Nasdaq delisting determination due to a stockholders' deficit of $(9,024,946), violating the $ | Oct 22, 2026 |
| RTSN | 8-K | neutral | 2/10 | Retension Pharmaceuticals appointed Robert Wong as Vice President, Chief Accounting Officer (Principal Accounting Office | Oct 22, 2026 |
| NTHI | 8-K | neutral | 3/10 | NeOnc Technologies filed an 8-K reporting three press releases: early clinical improvement in a single pediatric compass | Oct 22, 2026 |
| IRON | 8-K | bearish | 6/10 | Disc Medicine completed a $450M upsized public offering of 6M shares at $75/share, raising ~$422.4M net proceeds to exte | Oct 22, 2026 |
| SAFX | 8-K | mixed | 6/10 | XCF Global completed its all-stock business combination with Southern Energy Renewables and DevvStream, creating a verti | Oct 22, 2026 |
| SHPH | 8-K | bearish | 6/10 | Shuttle Pharmaceuticals dismissed its auditor, Forvis Mazars, effective after the Q3 2026 10-Q filing. The dismissal fol | Oct 22, 2026 |
| KNSA | 8-K | neutral | 2/10 | Kiniksa appointed Ross Moat as President and COO, effective immediately, with a base salary increase to $700,000 and tar | Oct 22, 2026 |
| AARD | 8-K | bullish | 7/10 | Aardvark Therapeutics announced that the FDA has lifted the clinical hold on its IND for ARD-101 for hyperphagia in Prad | Oct 22, 2026 |